Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025

Preliminary findings to be shared from Cohort C (active brain metastases) of the REZILIENT2 trial of zipalertinib in patients with exon 20 insertion (ex20ins) or other uncommon mutation epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) PRINCETON, N.J., July...

Read More